Laboratory of Human Anatomy, Department of Health Sciences, University of Piemonte Orientale, Novara, Italy; Laboratory for Biomaterials and Bioengineering, Canada Research Chair Tier I in Biomaterials and Bioengineering for the Innovation in Surgery, Department of Min-Met-Materials Engineering & CHU de Quebec Research Center, Laval University, Quebec City, Quebec, Canada.
Laboratory of Human Anatomy, Department of Health Sciences, University of Piemonte Orientale, Novara, Italy.
Adv Med Sci. 2019 Mar;64(1):144-151. doi: 10.1016/j.advms.2018.08.007. Epub 2019 Jan 17.
Endothelialisation of vascular substitutes, in fact, remains one of the most unsolved problems in cardiovascular diseases treatment. Stromal Derived Factor 1 (SDF-1) has been largely investigated as an endothelialisation promoter and Pleiotrophin is a promising alternative. Although it has been known to exert beneficial effects on different cell types, its potential as an inducer of proliferation and migration of endothelial cells was not investigated. Therefore, this work is aimed to compare the effects of Pleiotrophin on proliferation and migration of endothelial cells with respect to SDF-1.
MATERIALS/METHODS: Endothelial cell line EA.hy926 was treated with Pleiotrophin (50 ng/ml) or SDF-1 (50 ng/ml). Cell viability was evaluated by MTT assay and migration assays were performed in Transwell chambers. Wound healing potential was evaluated by scratch wound assay. CXCR4, RPTP β/ζ, PCNA and Rac1 expression was detected by Western Blot.
Interestingly, Pleiotrophin significantly increased the viability of the treated endothelial cells with respects to SDF-1. The migratory ability of the endothelial cells was also improved in the presence of Pleiotrophin with reference to the SDF-1 treatment. Moreover, Western Blot analysis showed how the treatment with Pleiotrophin can induce an increase in the expression of RPTP β/ζ, PCNA and Rac1 compared to SDF-1.
Due to the significant effects exerted on viability, migration and repair ability of endothelial cells compared to SDF-1, Pleiotrophin can be considered as an interesting molecule to promote re-endothelialisation.
血管替代物的内皮化实际上仍然是心血管疾病治疗中最未解决的问题之一。基质衍生因子 1（SDF-1）已被广泛研究作为内皮化促进剂，而多效蛋白是一种很有前途的替代品。尽管它已被证明对不同类型的细胞具有有益的作用，但它作为内皮细胞增殖和迁移诱导剂的潜力尚未得到研究。因此，这项工作旨在比较多效蛋白对内皮细胞增殖和迁移的影响与 SDF-1 的影响。
材料/方法：内皮细胞系 EA.hy926 用多效蛋白（50ng/ml）或 SDF-1（50ng/ml）处理。通过 MTT 测定评估细胞活力，通过 Transwell 室进行迁移测定。通过划痕愈合测定评估伤口愈合潜力。通过 Western Blot 检测 CXCR4、RPTP β/ζ、PCNA 和 Rac1 的表达。
有趣的是，与 SDF-1 相比，多效蛋白显著增加了处理后内皮细胞的活力。与 SDF-1 处理相比，多效蛋白也改善了内皮细胞的迁移能力。此外，Western Blot 分析表明，与 SDF-1 相比，多效蛋白处理可诱导 RPTP β/ζ、PCNA 和 Rac1 的表达增加。
由于与 SDF-1 相比，多效蛋白对内皮细胞的活力、迁移和修复能力具有显著影响，因此可以认为多效蛋白是促进再内皮化的一种有趣分子。
